IL160097A0 - Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof - Google Patents

Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Info

Publication number: IL160097A0
Authority: IL; Israel
Prior art keywords: ylidene; carboxamide; diethylamino; indole; pyrrole
Prior art date: 2001-08-15

Application number

IL16009702A

Other languages

English (en)

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-15

Filing date

2002-08-13

Publication date

2004-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL160097(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-13 Application filed by Upjohn Co filed Critical Upjohn Co

2004-06-20 Publication of IL160097A0 publication Critical patent/IL160097A0/xx

Links

-1 5-fluoro-2-oxo-3h-indole 3-ylidene Chemical group 0.000 title 1
239000013078 crystal Substances 0.000 title 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
150000004701 malic acid derivatives Chemical class 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Obesity (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)

IL16009702A 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof IL160097A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31235301P	2001-08-15	2001-08-15
PCT/US2002/025649 WO2003016305A1 (fr)	2001-08-15	2002-08-13	Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes

Publications (1)

Publication Number	Publication Date
IL160097A0 true IL160097A0 (en)	2004-06-20

Family

ID=23211067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16009702A IL160097A0 (en)	2001-08-15	2002-08-13	Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Country Status (42)

Country	Link
US (2)	US20030069298A1 (fr)
EP (3)	EP2332934B1 (fr)
JP (1)	JP4159988B2 (fr)
KR (1)	KR100639281B1 (fr)
CN (2)	CN100364991C (fr)
AP (1)	AP1660A (fr)
AR (1)	AR036261A1 (fr)
AU (1)	AU2002324684B2 (fr)
BG (1)	BG108553A (fr)
BR (1)	BR0211612A (fr)
CA (1)	CA2455050C (fr)
CO (1)	CO5550431A2 (fr)
CU (1)	CU23713B7 (fr)
CY (1)	CY1121552T1 (fr)
CZ (1)	CZ2004196A3 (fr)
DK (2)	DK3168218T3 (fr)
EA (1)	EA006445B9 (fr)
EC (1)	ECSP044975A (fr)
ES (3)	ES2705063T3 (fr)
GE (1)	GEP20063777B (fr)
HR (1)	HRP20040112B1 (fr)
HU (1)	HU229206B1 (fr)
IL (1)	IL160097A0 (fr)
IS (1)	IS7147A (fr)
MA (1)	MA27058A1 (fr)
ME (1)	ME00414B (fr)
MX (1)	MXPA04001452A (fr)
MY (1)	MY139383A (fr)
NO (1)	NO326508B1 (fr)
NZ (1)	NZ531232A (fr)
OA (1)	OA12650A (fr)
PL (1)	PL216524B1 (fr)
PT (2)	PT3168218T (fr)
RS (1)	RS53251B (fr)
SI (2)	SI3168218T1 (fr)
SK (1)	SK902004A3 (fr)
TN (1)	TNSN04028A1 (fr)
TR (1)	TR201900509T4 (fr)
TW (1)	TWI269796B (fr)
UA (1)	UA76483C2 (fr)
WO (1)	WO2003016305A1 (fr)
ZA (1)	ZA200400706B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GEP20063777B (en)	2001-08-15	2006-03-27	Upjohn Co	Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
PY0323128A (es) *	2002-09-10	2012-12-03	Pharmacia Italia Spa	Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas
EP1670785B1 (fr) *	2003-10-02	2010-07-07	Pharmacia & Upjohn Company LLC	Sels et polymorphes d'un compose d'indolinone a substitution pyrrolique
US20060009510A1 (en) *	2004-07-09	2006-01-12	Pharmacia & Upjohn Company Llc	Method of synthesizing indolinone compounds
PT1773811E (pt) *	2004-07-22	2010-10-19	Lilly Co Eli	Um hidrato cristalino variável de sal de hemissuccinato de (s)-6-(4-(2-((3-(9h-carbazol-4-iloxi)-2- hidroxipropil)amino)-2-metilpropil)fenoxi)-3-piridinicarbox amida
RU2007141654A (ru) *	2005-05-12	2009-05-20	Пфайзер Инк. (US)	Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат
NZ566033A (en)	2005-09-19	2011-04-29	Pfizer Prod Inc	Solid salt forms of a pyrrole substituted 2-indolinone
US20090004213A1 (en) *	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
US20100256392A1 (en) *	2007-11-21	2010-10-07	Teva Pharmaceutical Industries Ltd.	Polymorphs of sunitinib base and processes for preparation thereof
EP2220071A2 (fr) *	2007-11-21	2010-08-25	Teva Pharmaceutical Industries Ltd.	Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation
CN101939314B (zh) *	2007-12-12	2014-04-02	麦迪凯姆股份公司	3-吡咯取代的2-吲哚酮的多晶型物
EP2090306A1 (fr)	2008-02-13	2009-08-19	Ratiopharm GmbH	Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (fr)	2008-04-29	2009-11-04	Ratiopharm GmbH	Composition pharmaceutique comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-dimethyl-1H-pyrrole-3-carboxamide
WO2009104021A2 (fr) *	2008-02-21	2009-08-27	Generics [Uk] Limited	Nouveaux polymorphes et procédés de préparation
EP2098521A1 (fr) *	2008-03-06	2009-09-09	Ratiopharm GmbH	Formules cristallines de N-[2-(diéthylamino)éthyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidène)méthyl]-2,4-diméthyl-1H-pyrrole-3-carboxamide
CA2720164A1 (fr) *	2008-03-31	2009-10-08	Teva Pharmaceutical Industries Ltd.	Procedes de preparation de sunitinib et de sels de ce dernier
KR20100135910A (ko)	2008-04-16	2010-12-27	낫코 파마 리미티드	수니티닙 염기의 신규한 다형 형태
EP2292613B1 (fr) *	2008-05-23	2015-09-30	Shanghai Institute of Pharmaceutical Industry	Dérivés de dihydroindolinone
WO2009150523A1 (fr) *	2008-06-13	2009-12-17	Medichem, S.A.	Procédé de préparation d’un sel 2-indolinone malate à substitution 3‑pyrrole
EP2138167A1 (fr)	2008-06-24	2009-12-30	ratiopharm GmbH	Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (fr) *	2008-06-26	2009-12-30	Medichem, S.A.	Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole
CN102203085A (zh) *	2008-07-10	2011-09-28	基因里克斯(英国)有限公司	用于制备苹果酸舒尼替尼晶体形式的新方法
EP2342195B1 (fr) *	2008-07-24	2014-09-10	Medichem, S.A.	Formes cristallines d un sel de malate de 2-indolinone à substitution 3-pyrrole
WO2010011834A2 (fr) *	2008-07-24	2010-01-28	Teva Pharmaceutical Industries Ltd.	Sunitinib et ses sels et leurs polymorphes
CA2735084A1 (fr) *	2008-08-25	2010-03-04	Generics [Uk] Limited	Nouveaux polymorphes de sunitinib et leurs procedes de preparation
CN102197035A (zh) *	2008-08-25	2011-09-21	基因里克斯(英国)有限公司	舒尼替尼的结晶形式及其制备方法
EP2350056A1 (fr) *	2008-10-10	2011-08-03	Medichem, S.A.	Procédé pour la préparation d'un sel de malate de 2-indolinone substituée par pyrrole en position 3
EP2181991A1 (fr) *	2008-10-28	2010-05-05	LEK Pharmaceuticals D.D.	Nouveaux sels de sunitinib
EP2186809A1 (fr) *	2008-11-13	2010-05-19	LEK Pharmaceuticals D.D.	Nouvelle forme cristalline du malate de sunitinib
EP2896618A1 (fr) *	2009-01-02	2015-07-22	Hetero Research Foundation	Polymorphes du malate de sunitinib
SG173014A1 (en)	2009-01-16	2011-08-29	Exelixis Inc	Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
EP2255792A1 (fr)	2009-05-20	2010-12-01	Ratiopharm GmbH	Composition pharmaceutique pour n-[2-(diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1h-pyrrole-3-carboxamide
WO2011004200A1 (fr)	2009-07-10	2011-01-13	Generics [Uk] Limited	Nouveaux dérivés de pyrrole
CA2774634A1 (fr)	2009-09-16	2011-03-24	Ranbaxy Laboratories Limited	Sels de sunitinib
EP2499133A2 (fr) *	2009-11-12	2012-09-19	Ranbaxy Laboratories Limited	Procédé de préparation de la forme cristalline i du sel d'acide l-malique de sunitinib
US8916716B2 (en)	2009-11-19	2014-12-23	Ranbaxy Laboratories Limited	Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2011092664A1 (fr)	2010-01-29	2011-08-04	Ranbaxy Laboratories Limited	Formes cristallines du sel d'acide l-malique du sunitinib
WO2011100325A2 (fr)	2010-02-09	2011-08-18	Sicor Inc.	Polymorphes de sels de sunitinib
WO2011104555A2 (fr)	2010-02-25	2011-09-01	Generics [Uk] Limited	Nouveau procédé
AU2011222470A1 (en)	2010-03-04	2012-09-27	Ranbaxy Laboratories Limited	Process for the direct preparation of malic acid salt of sunitinib
US20160185760A1 (en)	2010-03-18	2016-06-30	Ranbaxy Laboratories Limited	Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (fr)	2010-04-16	2011-10-20	Generics [Uk] Limited	Procédés inédits
WO2012042421A1 (fr)	2010-09-29	2012-04-05	Pfizer Inc.	Procédé de traitement de la croissance cellulaire anormale
DK2699598T3 (en)	2011-04-19	2019-04-23	Pfizer	COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
ES2709110T3 (es)	2012-03-23	2019-04-15	Laurus Labs Ltd	Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido
PL399027A1 (pl)	2012-04-27	2013-10-28	Instytut Farmaceutyczny	Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
AU2013255511B2 (en)	2012-05-04	2016-01-28	Pfizer Inc.	Prostate-associated antigens and vaccine-based immunotherapy regimens
US9278955B2 (en)	2013-10-18	2016-03-08	Sun Pharmaceutical Industries Limited	Ascorbic acid salt of sunitinib
CA2838587A1 (fr) *	2013-10-18	2015-04-18	Hari Babu Matta	Forme cristalline pure ii de sel d'acide l-malique de sunitinib et procede pour sa preparation
JP2016535989A (ja)	2013-11-01	2016-11-24	ファイザー・インク	前立腺関連抗原を発現させるためのベクター
CN104693187A (zh) *	2013-12-10	2015-06-10	安杰世纪生物科技（北京）有限公司	一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) *	2013-12-25	2019-05-28	江苏豪森药业集团有限公司	苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) *	2014-10-01	2015-11-10	Олег Ростиславович Михайлов	КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) *	2014-12-05	2016-06-29	广州白云山医药集团股份有限公司白云山制药总厂	一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (fr)	2018-03-15	2019-09-18	MH10 Spolka z ograniczona odpowiedzialnoscia	Composition pharmaceutique de sunitinib ou de son sel dans sa forme polymorphe i
WO2020216450A1 (fr)	2019-04-25	2020-10-29	Synthon B.V.	Composition pharmaceutique comprenant du sunitinib amorphe
KR20220003512A (ko) *	2019-04-18	2022-01-10	미터 헬스, 인코포레이티드	호흡성 부정맥을 치료하기 위한 방법 및 조성물
JP7633786B2 (ja) *	2020-09-18	2025-02-20	日本化薬株式会社	スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko)	2022-08-19	2024-02-27	주식회사 스카이테라퓨틱스	무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL170330B1 (pl)	1990-10-15	1996-11-29	Pfizer	Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL
IL100091A (en)	1990-12-12	1998-08-16	Zeneca Ltd	Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
RO114326B1 (ro)	1992-06-05	1999-03-30	Merck Sharp & Dohme Limited Ho	Sarea sulfat a unui triazol substituit, procedeu de obtinere a acesteia, compozitie farmaceutica si procedeu de obtinere a acesteia
US5721359A (en)	1993-03-12	1998-02-24	Pharmacia & Upjohn Company	Crystalline ceftiofur free acid
US5665878A (en) *	1994-08-31	1997-09-09	Eli Lilly And Company	Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives
DE19503966C2 (de) *	1995-02-07	1998-07-02	Mack Chem Pharm	Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) *	1995-05-30	1997-01-28	Motorola, Inc.	Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) *	1995-07-06	1997-10-07	Moore; James R.	Instructional toothbrush
US20020045746A1 (en) *	1995-12-11	2002-04-18	Barton Kathleen P.	Eplerenone crystalline form
US20020038021A1 (en) *	1995-12-11	2002-03-28	Barton Kathleen P.	Eplerenone crystalline form exhibiting enhanced dissolution rate
US6066647A (en) *	1996-07-29	2000-05-23	Pfizer Inc.	Zwitterionic forms of trovafloxacin
TR199900298T2 (xx)	1996-08-14	1999-05-21	G.D. Searle &Co.	4-(5-Metil-3-fenilizoksazol-4-il) BenzenS�lfonamidin kristal halinde bi�imi.
CN1104378C (zh) *	1996-12-25	2003-04-02	日本化药株式会社	顺铂细粉及其制备方法
US5777185A (en) *	1997-09-09	1998-07-07	Laroche Industries Inc.	Production of organic fluorine compounds
US6133305A (en) *	1997-09-26	2000-10-17	Sugen, Inc.	3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) *	1998-01-26	2000-01-11	The Boeing Company	Galley vacuum waste disposal system
CN1275126A (zh)	1998-06-19	2000-11-29	帝人株式会社	2－(3－氰基－4－异丁氧基苯基)－4－甲基－5－噻唑甲酸的多晶型体及其制备方法
BR9916327A (pt) *	1998-12-17	2001-09-18	Hoffmann La Roche	Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
US6239141B1 (en)	1999-06-04	2001-05-29	Pfizer Inc.	Trovafloxacin oral suspensions
PT1233943E (pt) *	1999-11-24	2011-09-01	Sugen Inc	Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
SI1255752T1 (sl)	2000-02-15	2007-12-31	Pharmacia & Upjohn Co Llc	S pirolom substituirani zaviralci 2-indolinon protein kinaza
US6316672B1 (en) *	2001-01-31	2001-11-13	Grayson Walker Stowell	Form a of fluoxetine hydrochloride
GEP20063777B (en)	2001-08-15	2006-03-27	Upjohn Co	Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
WO2009104021A2 (fr)	2008-02-21	2009-08-27	Generics [Uk] Limited	Nouveaux polymorphes et procédés de préparation
WO2009156837A2 (fr)	2008-06-26	2009-12-30	Medichem, S.A.	Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole

2002
- 2002-08-13 GE GE5446A patent/GEP20063777B/en unknown
- 2002-08-13 OA OA1200400044A patent/OA12650A/en unknown
- 2002-08-13 KR KR1020047002173A patent/KR100639281B1/ko not_active Expired - Lifetime
- 2002-08-13 PT PT16196036T patent/PT3168218T/pt unknown
- 2002-08-13 SI SI200231093T patent/SI3168218T1/sl unknown
- 2002-08-13 DK DK16196036.4T patent/DK3168218T3/en active
- 2002-08-13 AP APAP/P/2004/002976A patent/AP1660A/en active
- 2002-08-13 SI SI200231043T patent/SI1419151T1/sl unknown
- 2002-08-13 SK SK90-2004A patent/SK902004A3/sk unknown
- 2002-08-13 PT PT2759342T patent/PT1419151E/pt unknown
- 2002-08-13 ES ES16196036T patent/ES2705063T3/es not_active Expired - Lifetime
- 2002-08-13 AU AU2002324684A patent/AU2002324684B2/en not_active Expired
- 2002-08-13 CA CA002455050A patent/CA2455050C/fr not_active Expired - Lifetime
- 2002-08-13 ME MEP-2008-520A patent/ME00414B/me unknown
- 2002-08-13 UA UA2004021084A patent/UA76483C2/uk unknown
- 2002-08-13 ES ES11156767.3T patent/ES2623094T3/es not_active Expired - Lifetime
- 2002-08-13 US US10/218,985 patent/US20030069298A1/en not_active Abandoned
- 2002-08-13 CN CNB2005101286242A patent/CN100364991C/zh not_active Expired - Lifetime
- 2002-08-13 ES ES02759342.5T patent/ES2453164T3/es not_active Expired - Lifetime
- 2002-08-13 HR HR20040112A patent/HRP20040112B1/xx not_active IP Right Cessation
- 2002-08-13 PL PL368317A patent/PL216524B1/pl unknown
- 2002-08-13 EP EP11156767.3A patent/EP2332934B1/fr not_active Expired - Lifetime
- 2002-08-13 EP EP02759342.5A patent/EP1419151B1/fr not_active Expired - Lifetime
- 2002-08-13 RS YU10304A patent/RS53251B/sr unknown
- 2002-08-13 CZ CZ2004196A patent/CZ2004196A3/cs unknown
- 2002-08-13 EA EA200400183A patent/EA006445B9/ru unknown
- 2002-08-13 JP JP2003521228A patent/JP4159988B2/ja not_active Expired - Lifetime
- 2002-08-13 NZ NZ531232A patent/NZ531232A/en not_active IP Right Cessation
- 2002-08-13 HU HU0700036A patent/HU229206B1/hu unknown
- 2002-08-13 BR BR0211612-0A patent/BR0211612A/pt not_active Application Discontinuation
- 2002-08-13 EP EP16196036.4A patent/EP3168218B1/fr not_active Expired - Lifetime
- 2002-08-13 WO PCT/US2002/025649 patent/WO2003016305A1/fr not_active Ceased
- 2002-08-13 IL IL16009702A patent/IL160097A0/xx active IP Right Grant
- 2002-08-13 TR TR2019/00509T patent/TR201900509T4/tr unknown
- 2002-08-13 CN CNB02815892XA patent/CN100439360C/zh not_active Ceased
- 2002-08-13 MX MXPA04001452A patent/MXPA04001452A/es active IP Right Grant
- 2002-08-13 DK DK02759342.5T patent/DK1419151T3/da active
- 2002-08-15 MY MYPI20023032A patent/MY139383A/en unknown
- 2002-08-15 TW TW091118419A patent/TWI269796B/zh active
- 2002-08-15 AR ARP020103088A patent/AR036261A1/es unknown
2004
- 2004-01-16 CO CO04002781A patent/CO5550431A2/es not_active Application Discontinuation
- 2004-01-28 ZA ZA2004/00706A patent/ZA200400706B/en unknown
- 2004-01-29 BG BG108553A patent/BG108553A/bg unknown
- 2004-02-10 EC EC2004004975A patent/ECSP044975A/es unknown
- 2004-02-10 IS IS7147A patent/IS7147A/is unknown
- 2004-02-11 MA MA27522A patent/MA27058A1/fr unknown
- 2004-02-12 CU CU20040029A patent/CU23713B7/es active IP Right Grant
- 2004-02-12 TN TNP2004000028A patent/TNSN04028A1/fr unknown
- 2004-03-12 NO NO20041054A patent/NO326508B1/no not_active IP Right Cessation
2007
- 2007-04-26 US US11/740,644 patent/US7435832B2/en not_active Expired - Lifetime
2018
- 2018-12-12 CY CY20181101336T patent/CY1121552T1/el unknown

Also Published As

Publication number	Publication date
HK1066542A1 (en)	2005-03-24
OA12650A (en)	2006-06-19
HRP20040112A2 (en)	2004-06-30
EP1419151A1 (fr)	2004-05-19
TWI269796B (en)	2007-01-01
ECSP044975A (es)	2004-03-23
BG108553A (bg)	2005-04-30
US20030069298A1 (en)	2003-04-10
MY139383A (en)	2009-09-30
SI1419151T1 (sl)	2014-04-30
EA006445B9 (ru)	2017-02-28
EP2332934B1 (fr)	2017-03-01
AP1660A (en)	2006-09-09
HRP20040112B1 (en)	2012-03-31
EP3168218A1 (fr)	2017-05-17
NO20041054L (no)	2004-03-12
PL216524B1 (pl)	2014-04-30
RS53251B (sr)	2014-08-29
JP4159988B2 (ja)	2008-10-01
CU20040029A7 (es)	2008-03-14
PT3168218T (pt)	2019-01-11
HK1088008A1 (zh)	2006-10-27
JP2005503386A (ja)	2005-02-03
CN100364991C (zh)	2008-01-30
HU229206B1 (en)	2013-09-30
MXPA04001452A (es)	2004-05-20
WO2003016305A1 (fr)	2003-02-27
GEP20063777B (en)	2006-03-27
IS7147A (is)	2004-02-10
TR201900509T4 (tr)	2019-02-21
EA006445B1 (ru)	2005-12-29
CN1789264A (zh)	2006-06-21
ES2705063T3 (es)	2019-03-21
SK902004A3 (sk)	2005-03-04
EA200400183A1 (ru)	2004-08-26
PL368317A1 (en)	2005-03-21
CA2455050C (fr)	2007-02-20
CN1543462A (zh)	2004-11-03
CN100439360C (zh)	2008-12-03
US7435832B2 (en)	2008-10-14
NZ531232A (en)	2004-11-26
CZ2004196A3 (cs)	2005-01-12
ES2623094T3 (es)	2017-07-10
EP3168218B1 (fr)	2018-11-14
TNSN04028A1 (fr)	2006-06-01
KR100639281B1 (ko)	2006-10-31
AP2004002976A0 (en)	2004-03-31
HUP0700036A2 (en)	2008-10-28
EP1419151B1 (fr)	2014-02-26
KR20040030074A (ko)	2004-04-08
PT1419151E (pt)	2014-03-27
ES2453164T3 (es)	2014-04-04
NO326508B1 (no)	2008-12-15
CY1121552T1 (el)	2020-05-29
MA27058A1 (fr)	2004-12-20
CA2455050A1 (fr)	2003-02-27
EP2332934A1 (fr)	2011-06-15
SI3168218T1 (sl)	2019-05-31
ME00414B (me)	2011-10-10
ZA200400706B (en)	2005-05-25
DK1419151T3 (da)	2014-03-31
AR036261A1 (es)	2004-08-25
UA76483C2 (en)	2006-08-15
CU23713B7 (es)	2011-10-05
RS10304A (sr)	2007-02-05
CO5550431A2 (es)	2005-08-31
US20070191458A1 (en)	2007-08-16
DK3168218T3 (en)	2019-01-14
AU2002324684B2 (en)	2006-10-05
BR0211612A (pt)	2004-08-24

Legal Events

Date	Code	Title
2010-10-31	FF	Patent granted
2010-10-31	KB	Patent renewed
2012-08-30	KB	Patent renewed
2016-07-31	KB	Patent renewed
2020-08-31	KB	Patent renewed

Publication	Publication Date	Title
IL160097A0 (en)	2004-06-20	Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
PT1488790E (pt)	2014-10-10	Preparação sólida contendo uma forma de cristal único a de um derivado de ácido tiazolcarboxílico
WO2002010154A3 (fr)	2002-06-27	Amides heterocycliques substitues
IL189359A0 (en)	2008-06-05	Novel process for the synthesis of 5 - (4 - fluorophenyl) - 1 - [2 - ((2r, 4r)- 4 - hydroxy - 6 - oxo -tetrahydro - pyran - 2 - yl) - ethyl] - 2 - isopropyl- 4 - phenyl - 1h - pyrrole - 3 - carboxylic acid phenylamide
WO2006025070A3 (fr)	2006-10-12	Nebivolol et ses sels pharmaceutiquement acceptables, procede de preparation et compositions pharmaceutiques de nebivolol
AP2001002330A0 (en)	2000-12-31	Polymorph of 5-¬4¬2-(n-methyl-n-(2 pyridyl) amino) ethocy¾ benyl¾ thiazoline-2, 4-dione maleic acid salt
IL141767A0 (en)	2002-03-10	Use of heteroaryl substituted n- (indole-2-carbonyl-) amides for treatment of infection
EP1619180A4 (fr)	2006-05-24	ANTAGONISTE DE CaSR
IL162456A0 (en)	2005-11-20	A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochlor
SI1600441T1 (sl)	2010-02-26	Kristalna oblika lerkanidipin hidroklorida za uporabo kot sredstvo proti hipertenziji
HUP0401694A3 (en)	2008-03-28	Crystal forms of a hydrochloride salt of a hydroxynorephedrine derivative, pharmaceutical compositions comprising thereof and use
AU2001267886A1 (en)	2002-01-14	Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
AU2003223637A1 (en)	2003-11-03	Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
PL368352A1 (en)	2005-03-21	Process for preparation of $g(a)-hydroxycarboxylic acid amides
HUP0202322A2 (en)	2002-10-28	A substantially crystalline form of melagatran, process for obtaining it, pharmaceutical composition containing thereof and its use
IL161275A0 (en)	2004-09-27	[[2-(amino-3,4-dioxo-1cyclobuten-1-yl) amino] alkyl] acid derivatives for the treatment of pain
IL162255A0 (en)	2005-11-20	Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
HK1045254A1 (zh)	2002-11-22	降低血小板黏性的处理方法
HK1044702A1 (zh)	2002-11-01	骨关节炎的治疗方法
AU2002364804A8 (en)	2003-06-10	Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses
EP1316547A4 (fr)	2005-10-12	Nouveaux cristaux de n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)- n-(4-phenoxyphenylcarbonyl)amino]pentanamide, leur procede de production et medicaments contenant ces cristaux en tant que substance active
AU2003243153A8 (en)	2003-11-10	Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
WO2004069790A3 (fr)	2005-02-17	Modification cristalline
PL372137A1 (en)	2005-07-11	A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochloride polymorphs and amorphous form
AU2001290743A1 (en)	2002-03-26	Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide